TIGIT (T cell immunoreceptor with Ig and ITIM domains) - The red hot corner of immune-oncology market drawing huge Interest
Interest in TIGIT has increased since last 2-3 years and several key players are now active in this field including BeiGene’s Ociperlimab, which is in Phase III stage of development for NSCLC; early and mid-stage active players include Innovent Biologics, BMS/Compugen, Astrazeneca, iTeos Therapeutics/GSK. Recently, in AACR, iTeos Therapeutics presented the data of its Anti-TIGIT Antibody, EOS-448/GSK4428859A, which is being developed in collaboration with GSK for the treatment of cancer. In clinical studies, the treatment with EOS-448 red...
